Search

Your search keyword '"Bettelheim, Peter"' showing total 18 results
Start Over Author "Bettelheim, Peter" Publisher wiley-blackwell
18 results on '"Bettelheim, Peter"'

2. Phenotypic characterization of disease‐initiating stem cells in JAK2‐ or CALR‐mutated myeloproliferative neoplasms.

Author

Ivanov, Daniel, Milosevic Feenstra, Jelena D., Sadovnik, Irina, Herrmann, Harald, Peter, Barbara, Willmann, Michael, Greiner, Georg, Slavnitsch, Katharina, Hadzijusufovic, Emir, Rülicke, Thomas, Dahlhoff, Maik, Hoermann, Gregor, Machherndl‐Spandl, Sigrid, Eisenwort, Gregor, Fillitz, Michael, Sliwa, Thamer, Krauth, Maria‐Theresa, Bettelheim, Peter, Sperr, Wolfgang R., and Koller, Elisabeth

Published
2023
Full Text
View/download PDF

3. Multicenter prospective evaluation of diagnostic potential of flow cytometric aberrancies in myelodysplastic syndromes by the ELN iMDS flow working group.

Author

Kern, Wolfgang, Westers, Theresia M., Bellos, Frauke, Bene, Marie Christine, Bettelheim, Peter, Brodersen, Lisa Eidenschink, Burbury, Kate, Chu, Sung‐Chao, Cullen, Matthew, Porta, Matteo Della, Dunlop, Alan Stewart, Johansson, Ulrika, Matarraz, Sergio, Oelschlaegel, Uta, Ogata, Kiyoyuki, Porwit, Anna, Preijers, Frank, Psarra, Katherina, Saft, Leonie, and Subirá, Dolores

Published
2023
Full Text
View/download PDF

4. Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group.

Author

Porwit, Anna, Béné, Marie C., Duetz, Carolien, Matarraz, Sergio, Oelschlaegel, Uta, Westers, Theresia M., Wagner‐Ballon, Orianne, Kordasti, Shahram, Valent, Peter, Preijers, Frank, Alhan, Canan, Bellos, Frauke, Bettelheim, Peter, Burbury, Kate, Chapuis, Nicolas, Cremers, Eline, Della Porta, Matteo G., Dunlop, Alan, Eidenschink‐Brodersen, Lisa, and Font, Patricia

Published
2023
Full Text
View/download PDF

5. ELN iMDS flow working group validation of the monocyte assay for chronic myelomonocytic leukemia diagnosis by flow cytometry.

Author

Wagner‐Ballon, Orianne, Bettelheim, Peter, Lauf, Jeroen, Bellos, Frauke, Della Porta, Matteo, Travaglino, Erica, Subira, Dolores, Lopez, Irene Nuevo, Tarfi, Sihem, Westers, Theresia M., Johansson, Ulrika, Psarra, Katherina, Karathanos, Serafeim, Matarraz, Sergio, Colado, Enrique, Gupta, Monali, Ireland, Robin, Kern, Wolfgang, and Van De Loosdrecht, Arjan A.

Published
2023
Full Text
View/download PDF

6. Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS‐Flow Cytometry Working Group.

Author

van de Loosdrecht, Arjan A., Kern, Wolfgang, Porwit, Anna, Valent, Peter, Kordasti, Sharham, Cremers, Eline, Alhan, Canan, Duetz, Carolien, Dunlop, Alan, Hobo, Willemijn, Preijers, Frank, Wagner‐Ballon, Orianne, Chapuis, Nicolas, Fontenay, Michaela, Bettelheim, Peter, Eidenschink‐Brodersen, Lisa, Font, Patricia, Johansson, Ulrika, Loken, Michael R., and te Marvelde, Jeroen G.

Published
2023
Full Text
View/download PDF

7. Long‐term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2‐year results from two pivotal phase 3 studies.

Author

Kulasekararaj, Austin G., Griffin, Morag, Langemeijer, Saskia, Usuki, Kensuke, Kulagin, Alexander, Ogawa, Masayo, Yu, Ji, Mujeebuddin, Arshad, Nishimura, Jun‐ichi, Lee, Jong Wook, Peffault de Latour, Régis, Latypova, Aigul, Barcellini, Wilma, Barraco, Fiorenza, Beam, Donald, Bettelheim, Peter, Borisenkova, Elena, Brodsky, Andres, Carnley, Benedict, and Cermak, Jaroslav

Subjects
PAROXYSMAL hemoglobinuria, LACTATE dehydrogenase
Abstract

Objectives: The complement component 5 (C5) inhibitor ravulizumab demonstrated non‐inferiority to eculizumab following 26 weeks of treatment in complement inhibitor‐naïve and complement inhibitor‐experienced patients with paroxysmal nocturnal hemoglobinuria (PNH; studies 301 and 302, respectively). This study aims to describe the results of both studies from 27 weeks to 2 years. Methods: Patients (N = 441) continued to receive ravulizumab throughout the extension period. Efficacy endpoints included lactate dehydrogenase (LDH) normalization, transfusion avoidance and fatigue score (FACIT‐F). Safety analyses were also performed. Results: From 27 weeks to 2 years, improvements in LDH levels were maintained in both study populations. Transfusion avoidance was maintained in 81.9% (study 301) and 85.6% (study 302) of patients, and FACIT‐F scores remained stable. Ravulizumab was well tolerated, and the incidence of adverse events (AEs) were similar between patients of both studies. Incidence of serious AEs deemed related to ravulizumab treatment was low (<3%). Conclusions: This study reports, to date, the longest period of follow‐up in over 400 patients with PNH treated with ravulizumab (662 patient‐years). Long‐term, ravulizumab demonstrated durable efficacy and was well tolerated, highlighting the importance of C5 inhibitors as the mainstay of PNH treatment. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

8. PD‐L1 overexpression correlates with JAK2‐V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms.

Author

Milosevic Feenstra, Jelena D., Jäger, Roland, Schischlik, Fiorella, Ivanov, Daniel, Eisenwort, Gregor, Rumi, Elisa, Schuster, Michael, Gisslinger, Bettina, Machherndl‐Spandl, Sigrid, Bettelheim, Peter, Krauth, Maria‐Theresa, Keil, Felix, Bock, Christoph, Cazzola, Mario, Gisslinger, Heinz, Kralovics, Robert, and Valent, Peter

Published
2022
Full Text
View/download PDF

9. Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia.

Author

Machherndl‐Spandl, Sigrid, Jäger, Eva, Barna, Agnes, Gurbisz, Michael, Marschon, Renate, Graf, Temeida, Graf, Elmir, Geissler, Christoph, Hoermann, Gregor, Nösslinger, Thomas, Pfeilstöcker, Michael, Bettelheim, Peter, Zach, Otto, Weltermann, Ansgar, Heibl, Sonja, Thaler, Josef, Zebisch, Armin, Sill, Heinz, Stauder, Reinhard, and Webersinke, Gerald

Subjects
CHRONIC leukemia, OLDER patients, TRANSFORMATION groups, PLATELET count, AGE
Abstract

In older patients with chronic myelomonocytic leukaemia (CMML) and limited life expectancy due to age and or comorbidities, it is particularly important to consider the risk of transformation for individualised treatment decisions. There is limited information on potential differences between younger and older CMML patients regarding the cumulative risk of transformation as well as haematological, molecular and biologic characteristics. We analysed data from the Austrian Biodatabase for CMML (ABCMML) to compare these parameters in 518 CMML patients. Categorisation of patients into 3 age‐related groups: <60 years, 60‐79 years and ≥80 years, showed a significantly lower risk of transformation at higher age by competing risk analysis, with a 4‐year risk of 39%, 23% and 13%, respectively (P <.0001). The lower probability of transformation was associated with a lower percentage of blast cells in the peripheral blood (PB) of older patients. Furthermore, we provide a simple score based on age, PB blasts and platelet counts that allowed us to define subgroups of CMML patients with a different cumulative transformation risk, including a low‐risk group with a transformation risk of only 5%. Our findings may facilitate reasonable treatment decisions in elderly patients with CMML. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

10. CD13 expression in B cell malignancies is a hallmark of plasmacytic differentiation.

Author

Raimbault, Anna, Machherndl‐Spandl, Sigrid, Itzykson, Raphaël, Clauser, Sylvain, Chapuis, Nicolas, Mathis, Stéphanie, Lauf, Jeroen, Alary, Anne‐Sophie, Burroni, Barbara, Kosmider, Olivier, Fontenay, Michaela, Béné, Marie C., Durrieu, Françoise, Bettelheim, Peter, and Bardet, Valérie

Subjects
B cells, LYMPHOPROLIFERATIVE disorders, PLASMA cells, FLOW cytometry, REGRESSION analysis
Abstract

Summary: The diagnosis of Waldenström Macroglobulinaemia (WM)/lymphoplasmacytic lymphoma (LPL) remains one of exclusion because other B‐cell lymphoproliferative disorders (B‐LPD), such as marginal zone lymphoma (MZL), can fulfil similar criteria, including MYD88 L265P mutation. It has been suggested that expression of the myeloid marker CD13 (also termed ANPEP) is more frequent in LPL than in other B‐LPD and has also been described on normal and malignant plasma cells. Here, CD13 expression was tested in a cohort of 1037 B‐LPD patients from 3 centres by flow cytometry. The percentage of CD13‐expressing cells was found to be variable among B‐LPD but significantly higher in WM/LPL (median 31% vs. 0% in non‐WM/LPL, P < 0·001). In multivariate linear regression, CD13 expression remained significantly associated with a diagnosis of WM/LPL (P < 0·001). A cut‐off value of 2% of CD19+ cells co‐expressing CD13 yielded the best diagnostic performance for WM/LPL assertion. This was further improved by association with the presence or absence of IgM paraprotein. Finally, given that previously published transcriptomic data revealed no difference in CD13 (also termed ANPEP) mRNA between normal and pathological B‐cells, the hypothesis of some post‐transcriptional regulation must be favoured. These results suggest that testing for CD13 expression in routine flow cytometry panels could help to discriminate WM/LPL from other B‐LPD. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

11. A European consensus report on blood cell identification: terminology utilized and morphological diagnosis concordance among 28 experts from 17 countries within the European LeukemiaNet network WP10, on behalf of the ELN Morphology Faculty Short Report.

Author

Zini, Gina, Bain, Barbara, Bettelheim, Peter, Cortez, José, d'Onofrio, Giuseppe, Faber, Edgar, Haferlach, Torsten, Kacirkova, Petra, Lewandowski, Krzysztof, Matutes, Estella, Maynadié, Marc, Meletis, John, Petersen, Bodil L., Porwit, Anna, Terpos, Evangelos, Tichelli, Andrée, Vallespí, Teresa, Woessner, Soledad, Bennett, John, and Bene, Marie C.

Subjects
HEMATOLOGY, BLOOD cells, MORPHOLOGY, LEUKEMIA
Abstract

This paper describes the methodology used to develop a consensual glossary for haematopoietic cells within Diagnostics-WP10 of European-LeukemiaNet EU-project. This highly interactive work was made possible through the use of the net, requiring only a single two-day meeting of actual confrontation and debate. It resulted in the production of a freely accessible tool that could be useful for training as well as harmonization of morphological reports in onco-haematology especially, without geographic limitation, not limited to European countries. Moreover, this collective work resulted in the production of a consensus statement, taking into account individual practices, collegial agreement and literature data. [ABSTRACT FROM AUTHOR]

Published
2010
Full Text
View/download PDF

16. Malignant histiocytosis with unusual features. Disseminated intravascular coagulation with severe hyperfibrinolysis, acute polyneuroradiculitis Guillain-Barré, and a unique chromosome abnormality.

Author

Haubenstock, Alexander, Base, Wolfgang, Bettelheim, Peter, Hinterberger, Wolfgang, Pavelka, Margit, Thaler, Erik, Radaszkiewicz, Thaddäus, Neumann, Erich, Schnedl, Wolfgang, Majdic, Otto, Lechner, Klaus, Haubenstock, A, Base, W, Bettelheim, P, Hinterberger, W, Pavelka, M, Thaler, E, Radaszkiewicz, T, Neumann, E, and Schnedl, W

Published
1984
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results